Compare Five Below Inc (FIVE) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Five Below Inc trades at $218.95 (market cap $11.75B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Five Below Inc is far larger — about 12.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Five Below Inc is more actively traded (742,657 versus 4,325,710). Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FIVE | MRVI | |
|---|---|---|
Market Cap | $11.75B | $972.90M |
Volume | 742,657 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $9.00 |
52-Week Low | $147.05 | $2.83 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | $12.60B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $218.95, up 2.51% today, with strong earnings momentum after beating Q1 and Q2 2026 estimates. The stock shows bearish technical signals but maintains solid fundamentals with 40.26% gross margins and 28.25% ROE. Recent news highlights growth initiatives including a $600M buyback and digital marketing push. Revenue growth accelerated from $3.6B in 2024 to $3.9B in 2025, with projected $5.3B in 2026.
FIVE presents a growth opportunity with analyst consensus target of $298.44 (36% upside), though execution risks remain. The premium valuation (P/E 19.14) requires sustained margin expansion amid consumer spending pressures. Institutional sentiment is bullish with 60% buy ratings, but technical weakness near resistance at $219 suggests near-term consolidation.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
